HRS In Brief
This article was originally published in The Gray Sheet
Data highlighted earlier this month at the Heart Rhythm Society annual conference in Boston include results for new ablation systems, quadripolar leads and antibacterial cardiac implant wraps.
You may also be interested in...
Medtronic has launched two more Attain Performa left ventricular quadripolar leads for the Viva Quad XT and Viva Quad S cardiac resynchronization therapy defibrillators following FDA approval announced Dec. 11. On the same day, St. Jude announced CE mark of the Quadra Allure MP cardiac resynchronization therapy pacemaker, the first quadripolar CRT-P with MultiPoint pacing.
Enrollment in CardioFocus’ U.S. pivotal trial of the HeartLight endoscopic atrial fibrillation ablation system is complete. A small study shows that small wires implanted in the head may cure chronic headaches. Biolase and Auris announce plans to build a cataract removal robot.
Biocon sees some wins for biosimilar adalimumab in the US and signals more opportunities amid the slower than anticipated build-out for Humira rivals. Chinese competition looms for glargine, but the Indian company declares it “will be competitive if these folks launch.”